-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The supplement "2021 China Nature Index" published on May 27th, based on the Nature Index data, shows China’s latest scientific research output in the field of natural sciences, and reveals the flow of Chinese scientific talents and international scientific research cooperation.
Among them, the article "Alzheimer's disease drug trial explores the relationship between the intestine and the brain" provides an in-depth report on the ninth phase one research and development team, showing the successful course of Professor Geng Meiyu and his team's 22-year research and development phase IX one.
Alzheimer's disease drug trial explores the connection between the gut and the brain
Alzheimer's disease drug trial explores the connection between the gut and the brainWith the help of new research methods to explore the relationship between the intestine and the brain, an innovative drug for Alzheimer's disease from China has provided us with new clues.
Looking at the world, dementia affects approximately 50 million people, and this number continues to grow at a rate of 10 million per year, more than half of which is attributed to Alzheimer’s disease.
Reshaping Alzheimer's disease treatment options
Reshaping Alzheimer's disease treatment optionsTraditional Alzheimer's disease drug research often focuses on the accumulation of β-amyloid in the brain and the neurofibrillary tangles caused by the hyperphosphorylation of Tau protein.
In 1997, Professor Geng Meiyu began to search for a sugar chain compound that would compete with glycosaminoglycans during the formation of β-amyloid fiber, thereby inhibiting the toxicity of β-amyloid fiber and reducing its presence in the brain.
She has extensively investigated a series of related factors and studies focusing on the association between Alzheimer's disease and intestinal flora.
Through cooperation with the Chinese pharmaceutical company Green Valley Pharmaceuticals, Geng Meiyu's 22-year research effort finally bears fruit.
Compared with drugs based on proteins and nucleic acids, the challenge of producing Manlutner capsules lies in the high structural complexity and diversity of sugar drugs.
Work together to create the future
Work together to create the futureIn 2019, Professor Geng Meiyu published in the journal Cell Research about the effects of a pair of mice in Phase 9 and the relationship between the dynamic changes of intestinal flora and neuroinflammation at different stages of Alzheimer's disease Research results.
However, this paper triggered a comment from an editor of the journal Cell Research, questioning the multiple targets claimed in the paper that can produce the therapeutic effect, and why there is no explanation of related side effects.
Professor Geng Meiyu explained that the research and development of Phase 9 and 1 proves that the development focus of China's pharmaceutical industry is shifting from the development of generic drugs to the development of original research drugs.
In a response article published in the journal Cell Research, Professor Geng Meiyu listed other multi-targeted drugs, such as metformin, a widely used oral drug for type II diabetes that targets multiple pathways to achieve The expected therapeutic effect.